Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck. He highlights progress in developing treatments for autoimmune diseases and anticipates milestones for the year ahead.
Copyright 2024 – Finance News Network
01 Mar 2022 - IVE Group Limited (ASX:IGL) Executive Chairman Geoff Selig discusses the highlights of the company's recently released results, key drivers and outlook.
07 Jun 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's phase 1 trial results for its chlorotoxin CAR T (CLTX CAR T) cell therapy targeting glioblastoma.
19 Dec 2019 - Renergen Limited (ASX:RLT) CEO Stefano Marani reveals the company's discovery of a 12% helium concentration reserve at the Virginia Gas Project in South Africa.
07 Jul 2021 - Knosys Limited (ASX:KNO Managing Director John Thompson provides an overview of the recent acquisition of LIBERO, a leading library management software business.
31 Oct 2023 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress of the company's drug candidates, highlighting promising data from the 2023 ESMO Congress.
29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
27 Apr 2020 - Kazia Therapeutics (ASX:KZA) CEO & MD, Dr. James Garner talks about its Phase II interim results for its glioblastoma drug candidate paxasilib, its pivotal GBM AGILE Phase II clinical study to commence 2H20 and value drivers as the company moves toward registration.
